Benign transient hyperphosphatasemia in children with leukemia and lymphoma

• Published in: Clinical pediatrics Vol. 35; no. 10; p. 501
• Main Authors: Massey, G V, Dunn, N L, Heckel, J L, Chan, J C, Russell, E C
• Format: Journal Article
• Language: English
• Published: United States 01-10-1996
• Subjects: Alkaline Phosphatase - blood; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone and Bones - enzymology; Child, Preschool; Female; Humans; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology; Remission Induction
• ISSN: 0009-9228
• DOI: 10.1177/000992289603501004

A temporary elevation of serum alkaline phosphatase has been described in young children who have no evidence of liver or bone disease. This phenomenon has been termed benign hyperphosphatasemia of infancy. Its occurrence is described in three children undergoing chemotherapy for acute lymphoblastic leukemia and lymphoma. All three children were in remission and in the consolidation or maintenance phase of their therapy when the hyperphosphatasemia occurred. All children were also receiving methotrexate (IM and IV), oral 6-mercaptopurine, and oral sulfamethoxazole/trimethoprim. Although these agents are associated with hepatotoxicity, other liver transaminases (ALT, AST) remained at normal concentrations, and there was an elevation only in the bone isoenzyme of alkaline phosphatase, thus making hepatic toxicity an unlikely etiology for the hyperphosphatasemia. No alteration in chemotherapy was necessary for resolution of the elevated alkaline phosphatase in these children.